Cathepsin K mRNA and protein expression in prostate cancer progression.
about
Manipulating substrate and pH in zymography protocols selectively distinguishes cathepsins K, L, S, and V activity in cells and tissuesChanges in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancerProstate cancer relevant antigens and enzymes for targeted drug deliveryCathepsin K inhibitors for osteoporosis and potential off-target effectsCathepsin K null mice show reduced adiposity during the rapid accumulation of fat storesSystematic optimization of multiplex zymography protocol to detect active cathepsins K, L, S, and V in healthy and diseased tissue: compromise among limits of detection, reduced time, and resources.Recent advances in bone-targeted therapies of metastatic prostate cancerAugmented osteolysis in SPARC-deficient mice with bone-residing prostate cancer.Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer.Cathepsin K is present in invasive oral tongue squamous cell carcinoma in vivo and in vitroMultiplex zymography captures stage-specific activity profiles of cathepsins K, L, and S in human breast, lung, and cervical cancerHoming of cancer cells to the boneMatrix-metalloproteinase-9 is cleaved and activated by cathepsin K.SERPINB13 is a novel RUNX1 target geneCysteine cathepsins in human cancer.Monocyte-derived macrophage assisted breast cancer cell invasion as a personalized, predictive metric to score metastatic risk.Proteolytic-antiproteolytic balance and its regulation in carcinogenesis.Anti-IL-20 Monoclonal Antibody Suppresses Prostate Cancer Growth and Bone Osteolysis in Murine Models.Potential role of odanacatib in the treatment of osteoporosis.Understanding and targeting osteoclastic activity in prostate cancer bone metastases.Interaction among cells of bone, immune system, and solid tumors leads to bone metastases.Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence.Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis.Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?Macrophage cathepsin K promotes prostate tumor progression in bone.Analysis of Argonaute Complex Bound mRNAs in DU145 Prostate Carcinoma Cells Reveals New miRNA Target Genes.Bone metastasis in prostate cancer: emerging therapeutic strategies.Cancer-associated lysosomal changes: friends or foes?Emerging drugs for the treatment of bone metastasis.Targeted Agents in Preclinical and Early Clinical Development for the Treatment of Cancer Bone Metastases.Photoactivated inhibition of cathepsin K in a 3D tumor model.Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.Mechanisms underlying the association between obesity and Hodgkin lymphoma.Synthesis and radiopharmacological characterisation of a fluorine-18-labelled azadipeptide nitrile as a potential PET tracer for in vivo imaging of cysteine cathepsins.Cathepsin K expression and activity in canine osteosarcoma.Collagen-gelatin mixtures as wound model, and substrates for VEGF-mimetic peptide binding and endothelial cell activation.Cathepsin K: a cysteine protease with unique kinin-degrading properties.LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
P2860
Q24594583-2FF3465C-8313-48B5-98D1-DE528C58C5E5Q24807354-4184D58B-99BE-40C6-BDBB-1DAFEADEE1E4Q27013843-F6D646FA-64DA-4EB2-88EA-99C080FA5C8EQ29042565-D62561BA-0BD8-4DAA-902E-4F53FEBD6360Q33292685-03562850-6DB2-417E-AA29-AC6A895AFEEFQ33439543-CEBB72F7-E99C-4ECD-91E7-6924BE172F06Q33703763-6F919E6A-4C6C-4AF1-87F6-1ACF3FB9A19AQ34497987-DC489EEF-C35C-4715-8DE9-B8A18A374193Q34768332-F7C02F69-AD0A-4171-9804-225531818A50Q34948094-9B20D10D-3CB7-4E0C-9F86-85AECA076B67Q35137318-361E5685-DB76-46A2-AE3D-5DDC3C9900C6Q35603135-B0E4E7FD-2502-4543-8888-8BBDACFA6966Q35720752-DFAF549E-7FB0-4437-8E01-CCF17EFE842DQ35851859-CCD03D47-669E-43A2-8050-5C6FB2013055Q35970409-5DE06B88-92BD-409F-A36B-756C2E8DAB91Q36039489-94DC8EDD-19A2-4A74-924D-F710161DD212Q36068428-A695FC51-AE8C-49FE-B2EA-8BB8D4AD515AQ36126224-7746CE9B-2718-449F-878D-1E758EFABB79Q36136239-FA28B422-91DA-4D41-B7B2-DDBD00925C43Q36759374-AB2DFB1E-0275-4BA6-8DA6-B6BF07B1BF41Q36848283-5B05CD5A-D64D-44AF-AF30-36279967F474Q37056336-3E486B08-7CAB-4555-89EF-58645F82B0A1Q37058788-36AD11B5-D290-42E4-9DFB-AAA283E6DF80Q37187646-FFA96E7A-C88C-4185-953F-7D201951E40EQ37316559-0E8105CE-8801-4769-A3E8-C336BE1826B2Q37428071-3696493A-8002-443D-B334-CA0FBC91B063Q37554550-15DAFD44-EBC1-401C-A3F3-9CB60CA5785EQ37597723-7420C158-5BF6-4468-917B-D5704F973D41Q37873719-69865E06-76E4-4259-884C-C93AB143CD17Q38025001-5BE22ACC-B3D8-4479-9FDA-3BCA9D8FABC7Q38538263-64E6CD47-0EBD-42F2-9861-B937D121CA0EQ38700342-E844CFB4-0F93-4860-9F37-547A6FC06333Q38791995-A32E1B5A-405F-442B-AFB2-DE91BD389E5CQ38895095-FD07E06B-6C41-4B0D-8DE0-10FD2C15047EQ38910560-FBDBC029-824E-488C-85C1-FABDCF59BB33Q39137404-7F1CABE4-5A68-4B8C-8FE4-4E0E87857C87Q39428117-3F9BD059-7059-40D4-87A2-3215FF6C9D70Q39825507-584B5FC3-7ACA-4EBA-9E27-1A4A689D0BE7Q41873108-8702538F-0269-40AE-9572-66C073F9FE83Q42315779-956310E9-A06F-493A-AF78-4179E84EAB1C
P2860
Cathepsin K mRNA and protein expression in prostate cancer progression.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Cathepsin K mRNA and protein expression in prostate cancer progression.
@en
Cathepsin K mRNA and protein expression in prostate cancer progression.
@nl
type
label
Cathepsin K mRNA and protein expression in prostate cancer progression.
@en
Cathepsin K mRNA and protein expression in prostate cancer progression.
@nl
prefLabel
Cathepsin K mRNA and protein expression in prostate cancer progression.
@en
Cathepsin K mRNA and protein expression in prostate cancer progression.
@nl
P2093
P2860
P1476
Cathepsin K mRNA and protein expression in prostate cancer progression.
@en
P2093
P2860
P304
P356
10.1359/JBMR.2003.18.2.222
P577
2003-02-01T00:00:00Z